In March, the pharmaceutical company Solaxa has announced plans to conduct a phase 3 clinical trial of their drug SLX-100 (repurposed 4-Aminopyridine) for Spinocerebellar ataxia 27b (SCA27b). The trial will be based in the US, but additional trial sites are to be announced later this year.
Read more here.
Read about 4-Aminopyridine here.
Take part in a challenge or create your fundraiser. Every penny you raise will help those affected by ataxia.
To make either a one off or recurring donation which will help fund research into treatments and cures and supports those affected ataxia
Support the ataxia community and volunteer with Ataxia UK. From social media to telephone befriending, there are loads of ways you can make a difference to someone's life.
